The Technion’s story has been intertwined with Israel’s for more than a century, from laying the foundations for a new nation to shaping its future.
Step inside Israeli innovation at the David and Janet Polak Visitors Center. Experience our 360° immersive movie and tech exhibition. Open to individuals and groups.
Learn MoreAs Seen in nocamels.com
There’s a common situation that occurs during a doctor’s visit. The patient comes in with an ailment, perhaps it’s a cough, a congested chest or ear ache. The doctor raises possibilities of what could be causing the sickness – pneumonia, strep throat, an ear infection and so on. Chests are listened to, ears are examined, noses are swabbed and some tests are sent off to the lab.
In the meantime, as the results may take days to come in, the doctor recommends that the patient get started on a round of antibiotics, making an educated guess to diagnose a possible bacterial infection and hoping to tackle it before it gets worse.
The doctor makes the best recommendation with the knowledge available at that moment.
Unfortunately, inefficient testing has led to the over-prescription of antibiotics, resulting in antimicrobial resistance (AMR), which is when bacteria become resistant to antibiotics.
NanoSynex Co-founders CEO Diane Abensur and COO Michelle Heymann are Technion alumnae. NanoSynex’s core technology was developed by Technion Professor Shulamit Levenberg, who now serves as the company’s Chief Scientific Advisor.